biomarkers Archives - Health Newscircle

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

March 18, 2024March 18, 2024

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment…

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

March 12, 2024March 12, 2024

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing,…

New Paper Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, Demonstrates Correlation Between the Presence of Misfolded α-Synuclein and Clinical Presentations of Alzheimer’s Disease

February 10, 2024February 10, 2024

Amprion is pleased to be affiliated with a new scientific paper published in Alzheimer’s & Dementia, entitled “Investigating alpha-synuclein co-pathology in…

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

February 6, 2024February 6, 2024

ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial…

Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases

November 14, 2023November 14, 2023

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related…